Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.72−0.03 (-1.71%)
Close on Nov 17, 2026Market cap $36.18MP/E –Yield –
Grace Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Grace Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$23.91M. For fiscal 2026 it was -$11.08M. The highest annual figure on record is -$11.08M in fiscal 2026.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$11.08M | – |
| FY2025 | Mar 31, 2025 | -$16.68M | – |
| FY2024 | Mar 31, 2024 | -$12.85M | – |
| FY2023 | Mar 31, 2023 | -$52.16M | – |
| FY2022 | Mar 31, 2022 | -$15.59M | – |
| FY2021 | Mar 31, 2021 | -$16.42M | – |
| FY2020 | Mar 31, 2020 | -$24.44M | – |
| FY2019 | Mar 31, 2019 | -$34.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$15.92M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$3.01M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$2.45M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$2.53M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$3.09M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$3.18M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$3.70M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$4.83M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$4.96M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$3.26M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$3.04M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$2.09M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$4.45M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$38.07M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$4.25M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$5.11M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$4.73M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$4.40M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$4.47M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$3.57M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$3.15M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.30M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$1.96M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$8.03M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$4.12M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$4.03M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$6.15M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$6.26M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$8.01M | – |
See a number that looks wrong?